Bank of America sees Eli Lilly's Foundayo as preferred oral GLP-1 [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America says could expand the obesity market without cannibalizing the company's existing Zepbound product. In a note to clients, Bank of America reiterated its Buy rating on Lilly, citing the early approval and favorable labeling of Foundayo, also known as orforglipron. Analysts described the therapy as the preferred oral GLP-1 due to its ease of use and lack of food restrictions. The bank adjusted near-term forecasts to account for launch pricing and expected early dose-mix, lowering its 2026 US revenue estimate to around $2 billion from $3 billion, while leaving full-year revenue largely unchanged at $82 billion. Its price target for Lilly shares was slightly raised to $1,294. Bank of America isprojecting roughly 90% of second-quarter prescriptions will come from lower-dose formulations priced at $149 and $199. Revenue is forecas
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First? [Yahoo! Finance]Yahoo! Finance
- Novo Says Weight-Loss Boom Is Just Beginning [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's Path to $1 Trillion Runs Directly Through the AI Boom [Yahoo! Finance]Yahoo! Finance
- 25th Annual Bio-IT World Conference & Expo in Boston Leads the Conversation on Operationalizing AI Across Real-World Drug Discovery Environments [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LLY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "stMarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website